Compare Heron Therapeutics Inc (HRTX) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B). The key difference: ABRDN Physical Gold Shares ETF is far larger — about 103.4× Heron Therapeutics Inc's market cap, and ABRDN Physical Gold Shares ETF is more actively traded (2,350,550 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| HRTX | SGOL | |
|---|---|---|
Market Cap | $68.01M | $7.03B |
Volume | 1,891,941 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.49 | $51.41 |
52-Week Low | $0.27 | $37.54 |
Typical Hold Time | 35 Days | 57 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
SGOL is trading at $39.02, down 1.66% with bearish technical signals dominating across moving averages and oscillators. The stock faces significant resistance at current levels with all support and resistance clustered around $39. Recent market sentiment reflects pressure from rising Treasury yields and Federal Reserve policy uncertainty, though some technical indicators like the 12-day RSI at 24.81 suggest potential oversold conditions.
The outlook remains challenging with persistent bearish momentum, though the deeply oversold RSI reading indicates potential for near-term stabilization. Investment opportunities exist for contrarian investors seeking gold exposure amid inflation concerns, while risks include continued pressure from rising interest rates and dollar strength that could push prices lower.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
